Nevada’s Vetoed Insulin Cost Transparency Bill Returns, as California Advances Several Pricing Measures Post author:Sam Post published:June 5, 2017 Post category:Drug Industry Daily Lawmakers in Nevada and California continue to target drugmakers in health care proposals. Source: Drug Industry Daily You Might Also Like Senator Criticizes FDA for Approach to Oxilofrine in Supplements April 8, 2016 FDA to Resume Unannounced Foreign Inspections Shortly, Says FDA Official December 20, 2021 J&J Alleges Amgen’s Proposed Biosimilar Infringes on Stelara Patents December 2, 2022